Cancer Therapy Shows Promise for Alzheimer's in Initial Study

An international research team has reported the initial application of a cancer therapy to address Alzheimer's disease. This information was released by the Weizmann Institute of Science on Monday, February 10.

The groundbreaking study marks the first time a cancer therapy, CAR-T, has been applied to address Alzheimer's disease, offering a new avenue for research.

Understanding CAR-T Therapy

CAR-T therapy, which was developed over three decades ago, involves genetically modifying a patient's immune cells to identify and target specific elements. This sophisticated approach has already transformed the treatment for certain blood cancers.

Targeting Alzheimer's Pathology

In a new study published in the U.S. journal Proceedings of the National Academy of Sciences (PNAS), researchers investigated the potential use of this therapy against Alzheimer's disease. Alzheimer's is characterized by the buildup of amyloid-beta protein plaques in the brain, alongside chronic inflammation.

Experimental Success in Mice

For the experiment, researchers extracted T cells from mice and engineered them to recognize amyloid proteins. These modified cells were then injected into mice exhibiting Alzheimer's-like pathology.

Following the treatment, the mice demonstrated a significant reduction in amyloid plaques and lower levels of brain inflammation.

The researchers stated that these findings represent an important initial step toward developing new immune-based treatments for Alzheimer's.

Future Horizons: Beyond Alzheimer's

The team added that this method could potentially be adapted for other neurodegenerative conditions, including amyotrophic lateral sclerosis and Parkinson's disease. It may also, in the future, assist in repairing brain damage caused by injury or stroke.